Daiichi Sankyo CO Ltd Ord(DSKYF)
OTC US

Today's Change
Delayed Last Update
Day Low16.1600
Day High17.0750
Open:17.0750
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Tipranks
Daiichi Sankyo Company (DSKYF) Receives a Buy from Macquarie
Tipranks
Citi Remains a Buy on Daiichi Sankyo Company (DSKYF)
Tipranks
Daiichi Sankyo Advances Dual Antibody-Drug Combo in Tough-to-Treat Breast Cancer
Tipranks
TD Cowen Remains a Buy on Daiichi Sankyo Company (DSKYF)
Tipranks
Macquarie Keeps Their Buy Rating on Daiichi Sankyo Company (DSKYF)
Tipranks
Daiichi Sankyo’s R-DXd Trial Sets Up Next Catalyst in Ovarian Cancer Treatment
Tipranks
Daiichi Sankyo’s New Phase 3 Ovarian Cancer Trial Sets the Stage for Future Growth
Tipranks
Daiichi Sankyo Delays Effective Date of Merger with Wholly Owned Subsidiary
Tipranks
New Ovarian Cancer Maintenance Trial Puts Daiichi Sankyo’s R-DXd in the Late-Stage Spotlight
Tipranks
Morgan Stanley Reaffirms Their Buy Rating on Daiichi Sankyo Company (DSKYF)
Tipranks
Citi Sticks to Its Buy Rating for Daiichi Sankyo Company (DSKYF)
Tipranks
Daiichi Sankyo Company (DSKYF) Receives a Buy from Goldman Sachs
Tipranks
Macquarie Sticks to Their Buy Rating for Daiichi Sankyo Company (DSKYF)
Tipranks
Daiichi Sankyo Expands Lung Cancer Pipeline With New DS-3939a Trial
Tipranks
Daiichi Sankyo Revises FY2026 Results After SG&A Accounting Error
Tipranks
Daiichi Sankyo Posts Strong Q1 Revenue Growth but Lower Net Profit, Lifts Dividend Outlook
Tipranks
Daiichi Sankyo Publishes Q1 FY2026 Consolidated Financial Reference Data
Tipranks
Daiichi Sankyo Flags Risks Around FY2026 Q1 Outlook and Pipeline Data
Tipranks
Daiichi Sankyo Extends ESOP-Based Share Grant Plan for U.S. Staff

Profile

Daiichi Sankyo Co Ltd was founded on September 28, 2005. The Company is engaged in the research, development, manufacture, sale and marketing of pharmaceutical products. Its principal products include Olmesartan, an anti-hypertensive agent; Prasugrel, an antiplatelet agent; Memary and Donepezil for the treatment of alzheimer's disease; Nexium for treating reflux esophagitis; Inavir, an anti-influenza treatment product; ActHIB, a haemophilus b conjugate vaccine; and Loxonin S, an analgesic and anti-inflammatory drug; Denosumab, an antibody for the treatment and prevention of various bone disorders; and Edoxaban, an oral anticoagulant product. The Company also markets therapies in hypertension, dyslipidemia, diabetes, acute coronary syndrome, and metastatic melanoma.
Market data provided by Barchart. Exchange delay details and data provider terms here. Information may be delayed, is provided 'as is' and is solely for informational purposes, and not for trading, investment or advice.